BAY-876 inhibited GLUT1 with good metabolic stability in vitro, had a high oral bioavailability in vivo, and its anticancer activity was demonstrated in a variety of cancers, including ovarian and triple-negative breast cancer [50,51]. This evidence concerns the gene SLC2A1 and cancer.